ORIGINAL RESEARCH article
Front. Pharmacol., 27 February 2024
Sec. Experimental Pharmacology and Drug Discovery
Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1345645
RETRACTED: Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1
- PC
Putri Cahaya Situmorang 1*
- SI
Syafruddin Ilyas 1
- RA
Rony Abdi Syahputra 2
- RM
Reka Mustika Sari 3
- AP
Alexander Patera Nugraha 4
- AI
Alek Ibrahim 5
1. Study Program of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, Indonesia
2. Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia
3. Research Center for Food Technology and Processing, National Research and Innovation Agency (BRIN), Yogyakarta, Indonesia
4. Department of Orthodontics, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, Indonesia
5. Research Center for Animal Husbandry, National Research and Innovation Agency (BRIN), Bogor, Indonesia
Summary
Citation
Situmorang PC, Ilyas S, Syahputra RA, Sari RM, Nugraha AP and Ibrahim A (2024) RETRACTED: Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1. Front. Pharmacol. 15:1345645. doi: 10.3389/fphar.2024.1345645
Received
30 November 2023
Accepted
19 February 2024
Published
27 February 2024
Retracted
29 January 2026
Volume
15 - 2024
Edited by
Onur Bender, Ankara University, Türkiye
Reviewed by
Dana Carmen Zaha, University of Oradea, Romania
Sirajudheen Anwar, University of Hail, Saudi Arabia
Updates
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.